Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Research & Development (2019 - 2025)

C4 Therapeutics' Research & Development history spans 7 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 23.16% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $104.2 million, down 5.78%, while the annual FY2025 figure was $104.2 million, 5.78% down from the prior year.
  • Research & Development reached $25.0 million in Q4 2025 per CCCC's latest filing, down from $26.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.5 million in Q4 2024 to a low of $20.5 million in Q1 2021.
  • Average Research & Development over 5 years is $27.3 million, with a median of $26.8 million recorded in 2021.
  • Peak YoY movement for Research & Development: surged 34.51% in 2022, then decreased 23.16% in 2025.
  • A 5-year view of Research & Development shows it stood at $26.6 million in 2021, then grew by 15.45% to $30.7 million in 2022, then dropped by 0.85% to $30.4 million in 2023, then rose by 6.98% to $32.5 million in 2024, then fell by 23.16% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Research & Development are $25.0 million (Q4 2025), $26.0 million (Q3 2025), and $26.2 million (Q2 2025).